Restoril - Clinical information

Restoril™ (temazepam) capsules

Consider a wide range of patient use¹

Restoril™ 7.5 mg (temazepam) capsules are appropriate for most patient populations, including patients with hepatic insufficiencies. The recommended 7.5 mg low dose is especially appropriate for elderly patients as there is little concern for drug-related interactions, plus it provides enhanced safety.

With Restoril™ (temazepam), age has a minimal effect on drug performance so it’s generally suitable for patients of all ages.² And, since approximately 7 million Restoril™ (temazepam) prescriptions are written annually,³ you can be confident in your prescription choice.

Important safety information: Restoril™ is indicated for the short-term treatment of insomnia (generally 7 to 10 days). The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Restoril™ is contraindicated in women who are pregnant or may become pregnant because of the potential risk to the fetus. The most common side effects of Restoril™ are drowsiness, dizziness, lightheadedness, and difficulty with coordination. Severe allergic reactions have been reported in patients taking sedative-hypnotics, including Restoril™. Complex behaviors such as “sleep driving” have also been reported. Although behaviors such as “sleep driving” may occur with Restoril™ alone at therapeutic doses, the use of alcohol or other CNS depressants with Restoril™ appears to increase the risk of these unusual behaviors, as does the use of Restoril™ doses exceeding the maximum recommended dose. Use extreme care while doing anything that requires complete alertness, such as driving a car, operating machinery, or piloting an aircraft.

Healthcare Provider Letter

For more information about Restoril™ (temazepam) capsules, please read the complete prescribing information.

References:
1. Restoril™ (temazepam) capsules complete prescribing information, Mallinckrodt Inc.
2. Greenblatt DJ, Shader RI, Marmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol. 1989;29:866-872.
3. Data on file, Mallinckrodt Inc.